CPHI · China Pharma Holdings, Inc. · Financials
$0.71
0.00 (-0.14%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$31.13M
Shares
43.02M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4.14M
-8.5%
FY2025
Net Income
-$3.19M
+32.7%
FY2025
Gross Margin
-3.18%
+40.7pp
FY2025
Operating Margin
-78.16%
+23.2pp
FY2025
Diluted EPS
-$0.74
+72.7%
FY2025
Operating Cash Flow
$148.26K
+136.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.91M | $4.14M | $4.53M | $7.01M | $8.1M | $9.64M | $10.87M | $10.92M | $12.33M | $13.21M | $15.57M | $20.35M | $22.13M | $32.81M | $54.51M | $81.17M | $74.39M | |
| $3.45M | $4.28M | $6.51M | $7.29M | $8.6M | $9.29M | $8.91M | $9.44M | $10.36M | $10.74M | $12.35M | $15.78M | $17.22M | $23.41M | $38.66M | $52.18M | $44.11M | |
| $460.17K | -$131.95K | -$1.99M | -$281.09K | -$493.92K | $349.27K | $1.95M | $1.48M | $1.97M | $2.47M | $3.22M | $1.46M | $2.67M | -$480.92K | $14.08M | $28.99M | $30.28M | |
| — | -3.18% | -43.84% | -4.01% | -6.09% | 3.62% | 17.97% | 13.57% | 16.02% | 18.68% | 20.67% | 7.2% | 12.05% | -1.47% | 25.82% | 35.71% | 40.71% | |
| $333.26K | $280.9K | $283.94K | $240.08K | $185.86K | $318.96K | $377.96K | $229.64K | $172.38K | $90.47K | $365.97K | $961.9K | $2.8M | $1.68M | $438.66K | — | — | |
| $4.11M | $2.45M | $1.78M | $1.47M | $1.89M | $1.65M | $1.82M | $2.29M | $1.95M | $2.02M | $2.27M | $1.9M | $1.72M | $2.4M | $2.87M | $3.72M | $3.04M | |
| $2.31M | $851.61K | $447.25K | $223.8K | $36.56K | $38.11K | $35.65K | $57.67K | $115.14K | $165.39K | $262.91K | — | — | — | — | — | — | |
| $2.94M | $1.5M | $2.62M | $2.75M | $2.7M | $3.09M | $2.68M | $2.93M | $3.26M | $3.29M | $3.08M | $3.6M | $1.79M | $1.61M | $1.46M | $1.17M | $1.51M | |
| $4.84M | $3.11M | $2.6M | $2.47M | $3.06M | $3.21M | $4.53M | $21.89M | $12.42M | $21.15M | $11.72M | $17.4M | $41.49M | $18.13M | $8.31M | $7.26M | $6.09M | |
| -$4.38M | -$3.24M | -$4.59M | -$2.75M | -$3.55M | -$2.86M | -$2.58M | -$20.41M | -$10.45M | -$18.68M | -$8.16M | -$14.3M | -$38.76M | -$18.61M | $5.91M | $22.03M | $24.66M | |
| — | -78.16% | -101.32% | -39.25% | -43.79% | -29.67% | -23.73% | -186.82% | -84.73% | -141.38% | -52.38% | -70.26% | -175.11% | -56.72% | 10.83% | 27.14% | 33.16% | |
| -$1.44M | -$1.74M | -$1.97M | $1833 | -$848.44K | $227.31K | $101.18K | -$17.48M | -$7.19M | -$15.39M | -$5.08M | -$10.7M | -$36.97M | -$16.99M | $7.37M | $23.2M | $26.17M | |
| $32.11K | $27.27K | $27.35K | $30.57K | $434.62K | $542K | $294.16K | $321.72K | $451.26K | $539.33K | $849.56K | -$1.17M | $785.8K | -$348.7K | -$308.38K | -$255.2K | -$168.26K | |
| — | — | — | $6602 | $10.76K | $3035 | $5675 | $27.53K | $38.52K | $64.41K | $130.58K | $119.93K | $69.74K | $8457 | $4944 | $7208 | $15.41K | |
| -$97.44K | $51.52K | -$147.5K | -$327K | -$423.86K | -$538.97K | -$288.48K | -$294.19K | -$412.74K | -$474.92K | -$718.98K | — | — | — | -$303.43K | $686.27K | — | |
| -$4.47M | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.4M | -$2.87M | -$20.7M | -$10.86M | -$19.15M | -$8.87M | -$15.35M | -$39.47M | -$18.95M | $5.6M | $22.71M | $1.44M | |
| — | — | — | — | — | — | — | — | -$109.99K | $122.63K | $308.18K | $60.44K | -$77.04K | -$1.06M | -$983.92K | -$3.44M | -$2.69M | |
| -$4.47M | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.4M | -$2.87M | -$20.7M | -$10.75M | -$19.28M | -$9.18M | -$15.41M | -$39.55M | -$20.01M | $4.62M | $19.27M | $23.41M | |
| — | -76.91% | -104.58% | -43.91% | -49.02% | -35.26% | -26.38% | -189.51% | -87.18% | -145.91% | -58.97% | -75.7% | -178.69% | -60.99% | 8.47% | 23.74% | 31.48% | |
| -$3.19M | -$2.92M | -$4.87M | -$3.2M | -$4.96M | -$3.18M | -$2.1M | -$20.44M | -$12.87M | -$15.84M | — | — | — | — | $5.89M | $24.35M | $27.14M | |
| USD/shares | -$0.42 | -$0.74 | -$2.71 | -$9.10 | -$37.80 | -$37.00 | — | — | — | — | — | -$175.00 | -$455.00 | -$230.00 | $55.00 | $220.00 | $270.00 |
| USD/shares | -$0.42 | -$0.74 | -$2.71 | -$9.10 | -$37.80 | -$37.00 | — | — | — | — | — | -$175.00 | -$455.00 | -$230.00 | $55.00 | $220.00 | $270.00 |
| shares | — | 4.29M | 1.75M | 338.36K | 105.14K | 92.26K | 87.25K | 87.16K | 87.16K | 87.16K | 87.16K | 87.16K | 87.16K | — | — | — | — |
| shares | — | — | — | — | — | 92.26K | 87.25K | 87.16K | 87.16K | 87.16K | 87.16K | 87.16K | 87.16K | — | 87.16K | 86.96K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.83×
EV/EBIT
—
Peer median 8.61×
P/E (TTM)
—
Peer medians compare against the 41 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Domestic Pharmaceuticals | $9,641,925 | $9,132,216 |
| COVID19 Testers | — | $1,734,233 |
Key facts
CIK
1106644
CUSIP
16941T401
13F (30d)
1 filings
1 filers